These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35078923)

  • 1. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
    Hecht M; Eckstein M; Rutzner S; von der Grün J; Illmer T; Klautke G; Laban S; Hautmann MG; Brunner TB; Tamaskovics B; Hinke A; Zhou JG; Frey B; Donaubauer AJ; Becker I; Semrau S; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Gostian AO; Fietkau R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
    Hecht M; Gostian AO; Eckstein M; Rutzner S; von der Grün J; Illmer T; Hautmann MG; Klautke G; Laban S; Brunner T; Hinke A; Becker I; Frey B; Semrau S; Geppert CI; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Fietkau R
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Jensen AD; Krauss J; Weichert W; Bergmann ZP; Freier K; Debus J; Münter MW
    Radiat Oncol; 2011 Sep; 6():122. PubMed ID: 21942981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
    Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
    Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01).
    Xu T; Shen C; Zhou X; Zhu L; Xiang J; Wang Y; Zhu Y; He X; Ying H; Wang Y; Ji Q; Hu C; Lu X
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):169-178. PubMed ID: 37574169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
    Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
    BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
    Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
    Johnson JM; Vathiotis IA; Harshyne LA; Ali A; Bar Ad V; Axelrod R; Lorber E; Curry J; Cognetti DM; Luginbuhl AJ; Tuluc M; Keith S; Mahoney MG; Argiris A
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
    Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
    Kim CG; Hong MH; Kim D; Lee BH; Kim H; Ock CY; Kelly G; Bang YJ; Kim G; Lee JE; Kim C; Kim SH; Hong HJ; Park YM; Sim NS; Park H; Park JW; Lee CG; Kim KH; Park G; Jung I; Han D; Kim JH; Cha J; Lee I; Kang M; Song H; Oum C; Kim S; Kim S; Lim Y; Kim-Schulze S; Merad M; Yoon SO; Kim HJ; Koh YW; Kim HR
    Clin Cancer Res; 2024 May; 30(10):2097-2110. PubMed ID: 38457288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
    Rosenberg AJ; Agrawal N; Juloori A; Cursio J; Gooi Z; Blair E; Chin J; Ginat D; Pasternak-Wise O; Hasina R; Starus A; Jones FS; Izumchenko E; MacCracken E; Wolk R; Cipriani N; Lingen MW; Pearson AT; Seiwert TY; Haraf DJ; Vokes EE
    JAMA Oncol; 2024 Jul; 10(7):923-931. PubMed ID: 38842838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.